English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNCCN 2023 Annual Congress: Hematologic Malignancies features expert perspectives on developments in blood cancer treatment, including NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Updates, CAR T-Cell therapy, BTK Inhibitors, Bispecific T-Cell Engagers, and More. The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square.
Tag: hematologic malignancies
Experts Available for Comment during Blood Cancer Awareness Month
Rutgers Cancer Institute of New Jersey, the state’s leading cancer center and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, is home to a team of the nation’s most experienced physicians with expertise in routine, rare and complex hematologic…
Delaying antibiotics for neutropenic fever may not affect survival of cancer inpatients
In cancer patients with neutropenic fever, delaying antibiotic treatment past 60 minutes from the time of fever detection does not reduce the short-term chance of survival, according to a study in the American Journal of Medical Quality. The journal is published in the Lippincott portfolio by Wolters Kluwer.
St. Jude Comprehensive Cancer Center receives Merit Extension Award from NCI
The St. Jude Comprehensive Cancer Center award extends its current $35 million, five-year Cancer Center Support Grant (CCSG) for an additional two years.
Examining Clostridium Difficile Infection in Blood and Marrow Transplant and Leukemic Patients
Members of the Hematologic Malignancies Program at Rutgers Cancer Institute of New Jersey examined the utilization of a low dose of oral vancomycin, a drug used at higher doses to treat established Clostridium difficile infection (CDI), as a way to prevent CDI in blood and bone marrow transplant (BMT) patients.
New Guidelines for Maximizing Cures and Minimizing Side Effects in Children with Hodgkin Lymphoma
The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.
New NCCN Resource for Understanding Childhood Leukemia
NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.
NCCN Meeting on Blood Cancers Will Be Virtual for the First Time
The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies (#NCCNhem2020) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online October 8-10.
Likelihood of Prenatal Screening for Blood Disorders Varies Between Type of Healthcare Provider
A Rutgers Cancer Institute of New Jersey investigator and other collaborators examined prenatal screening practices for blood disorders between different types of care providers and found different variations in prenatal guidance.
Addition of Post-Transplant Chemotherapy to Standard Immune Treatment Shows Increase of Allogeneic Transplant Patients in Remission
Rutgers Cancer Institute of New Jersey investigators compared outcomes for allogeneic stem cell transplant patients when post-transplant cyclophosphamide (PCy) was added as part of standard treatment than if standard treatment was given alone. Results showed an increase in the number of patients who were free of disease and off immunosuppression at one-year in the PCy cohort.